SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-077820
Filing Date
2022-03-17
Accepted
2022-03-17 07:30:56
Documents
14
Period of Report
2022-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d316236d8k.htm   iXBRL 8-K 25782
2 EX-99.1 d316236dex991.htm EX-99.1 123679
6 GRAPHIC g316236dsp004.jpg GRAPHIC 9930
  Complete submission text file 0001193125-22-077820.txt   297314

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fusn-20220317.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20220317_lab.xml EX-101.LAB 18690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20220317_pre.xml EX-101.PRE 11695
8 EXTRACTED XBRL INSTANCE DOCUMENT d316236d8k_htm.xml XML 3517
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 22746733
SIC: 2836 Biological Products, (No Diagnostic Substances)